Koji Atarashi

This inventor holds 37 USPTO granted patents and 13 published patent applications, plus 2 CIPO patents and 10 EPO patents, primarily in Regulatory T Cells. Top assignees: The University of Tokyo, Azabu Veterinary Medicine Educational Institution, Keio University. Active years: 2016-2025.

USPTO Granted Patents = 37 (Patent Applications = 13)

% Patents Active = 97.3

CIPO Patents = 2 (Patent Applications = 8)

EPO Patents = 10 (Patent Applications = 17)

Average Co-Inventor Count = 4.6

ph-index = 16

Forward Citations = 779(Granted Patents)

Location History:

Yokohama, JP (2017 - 2018)
Wako, JP (2019 - 2023)
Tokyo, JP (2016 - 2024)

Company Filing History:

29 out of 1,351

The University of Tokyo

patents

12 out of 15

Azabu Veterinary Medicine Educational Institution

Vedanta Biosciences, Inc.

School Corporation, Azabu Veterinary Medicine Educational Institute

patent

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

Areas of Expertise:

Regulatory T Cells

Bacteriophage

Inflammatory Bowel Disease

TH1 Cells

Bioactive Molecules

Microbiota

CD8+ T-Cells

TH17 Cells

Human-Derived Bacteria

Proliferation Induction

Composition

Anti-Bacterial

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12502411 - HUMAN-DERIVED BACTERIA THAT INDUCE PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS (2025-12-23),

2. 12409196 - Composition for inducing proliferation or accumulation of regulatory T cells (2025-09-09),

3. 12390499 - Bacteriophage for modulating inflammatory bowel disease (2025-08-19),

4. 12285475 - Bacterium capable of inducing TH1 cells (2025-04-29),

5. 12214003 - Composition for inducing proliferation or accumulation of regulatory T cells (2025-02-04),

6. 12036249 - Anti-bacterial composition against TH1 cell-inducing bacteria (2024-07-16),

7. 11826424 - Compositions and methods for induction of Th17 cells (2023-11-28),

8. 11723934 - Compositions and methods for the induction of CD8+ T-cells (2023-08-15),

9. 11633433 - Anti-bacterial composition against TH1 cell-inducing bacteria (2023-04-25),

10. 11547732 - Human-derived bacteria that induce proliferation or accumulation of regulatory T cells (2023-01-10),

11. 11090343 - Composition for inducing proliferation or accumulation of regulatory T cells (2021-08-17),

12. 10835559 - Human-derived bacteria that induce proliferation or accumulation of regulatory T cells (2020-11-17),

13. 10624933 - Human-derived bacteria that induce proliferation or accumulation of regulatory T cells (2020-04-21),

14. 10588925 - Composition for inducing proliferation or accumulation of regulatory T cells (2020-03-17),

15. 10555978 - Composition for inducing proliferation or accumulation of regulatory T cells (2020-02-11),

Title: The Innovative Journey of Koji Atarashi: Pioneering Advances in Biomedical Science

Introduction:

Koji Atarashi, a distinguished inventor based in Tokyo, Japan, has made significant contributions to the field of biomedical science. With a remarkable portfolio of 32 patents to his name, Atarashi continues to push the boundaries of innovation in his research endeavors.

Latest Patents:

Atarashi's recent patents showcase his groundbreaking work in developing anti-bacterial compositions against TH1 cell-inducing bacteria. Through his research, he has identified intestinal bacteria that can suppress the colonization of oral bacteria, leading to the development of novel compositions and methods for inducing Th17 cells. These pharmaceutical compositions hold immense potential as anti-infectives and adjuvants in mucosal vaccines, highlighting Atarashi's pioneering approach to combatting infectious diseases.

Career Highlights:

Throughout his career, Atarashi has been associated with esteemed institutions such as The University of Tokyo and the Azabu Veterinary Medicine Educational Institution. His affiliation with these renowned organizations underscores his commitment to advancing scientific knowledge and fostering innovation in the field of biomedicine.

Collaborations:

Atarashi's collaborative efforts with esteemed colleagues, including Kenya Honda and Takeshi Tanoue, have been instrumental in shaping the trajectory of his research. Together, they have explored the intricate interplay between the microbiota and the immune system, leading to the discovery of novel therapeutic interventions for various medical conditions.

Conclusion:

In conclusion, Koji Atarashi's unwavering dedication to innovation and his pioneering contributions to biomedical science have solidified his reputation as a visionary inventor. His inventive spirit and collaborative efforts continue to drive the development of novel solutions that have the potential to revolutionize the healthcare industry.